ZEV MUNK, MD, FRCP(C), FACP, FOUNDER AND CHAIRMAN OF THE BOARD
Dr. Zev Munk founded Pharm-Olam in 1994, and is currently Chairman of Pharm-Olam International. His vision and strong leadership provides the executive oversight which has allowed the company to grow significantly since its inception. For more than twenty years, his commitment to clients, quality, and value have firmly established Pharm-Olam as a leading full-service clinical solutions company.
A graduate of McGill University School of Medicine in Montreal, Dr. Munk completed specialist training in internal medicine, and allergy and immunology, and has a wide range of expertise with over thirty years of experience in clinical research. His credentials include; Fellow of the Royal College of Physicians and Surgeons of Canada, Fellow of the American College of Physicians, Fellow of the American College of Allergy, and Fellow of the American Association of Allergy, Immunology, and Asthma. As a clinician and researcher, Dr. Munk’s wealth of knowledge and vision for the future allows Pharm-Olam to continually grow and excel in the development of therapies for many diseases.
EUGENE BARG, FOUNDING PARTNER AND BOARD MEMBER
Eugene Barg is a joint founder of Pharm-Olam International and its subsidiary, MB Quest, Inc., with Dr. Zev Munk. Mr. Barg has over 20 years’ experience in the clinical research field including positions as Head of Quality Assurance and Director of International Business Development. He used this extensive hands-on experience during the creation of MB Quest in 1997 to focus on the emerging markets of Russia, Ukraine, Georgia, Belarus and Kazakhstan. Under his supervision, Pharm-Olam became one of the top international CROs working in the region.
As a Board Member, Mr. Barg provides strategic vision and leadership for the entire organization, while ensuring that all quality metrics and standards are met or exceeded on a global level.
DAVID L. GRANGE, CHIEF EXECUTIVE OFFICER
David L. Grange is the CEO of Pharm-Olam International, LLC, which provides a full range of clinical support to pharma and bio-tech companies. Pharm-Olam is headquartered in Houston, Texas and operates globally with regional offices in Research Triangle Park, North Carolina and Bracknell, United Kingdom. Mr. Grange departed PPDI (Pharmaceutical Product Development, Inc.), a clinical research organization, in 2011 as CEO and as a member of the Board of Directors since 2003. As CEO he was responsible for the oversight of company clinical and laboratory operations and personnel in over 100 countries with 10,500 employees providing clinical and laboratory services to the majority of the top global pharmaceutical and biotech companies, as well as government health and research organizations.
Prior to joining PPDI, Mr. Grange served in the McCormick Foundation for 9.5 years, as President and Chief Executive Officer and earlier as Executive Vice President and Chief Operating Officer. The Foundation, one of the largest philanthropic organizations in the United States, works to advance the ideals of a free, democratic society by investing in children, communities, and country, and has granted more than $1.5 billion to organizations across the nation.
Mr. Grange served 30 years in the U.S. Army, leading from platoon through division level, with a decorated military career. His final assignments before retiring were commanding peace support operations in the Balkans. Following 9-11, Mr. Grange was a national security consultant for CNN, CBS, and WGN. He regularly speaks and writes for a variety of companies and government institutions on leadership, organizational effectiveness, disaster preparedness, citizenship, Veterans issues, and foreign relations at home and abroad.
Mr. Grange holds a bachelor’s degree from North Georgia College and a master’s in public service from Western Kentucky University. In addition, he is the recipient of an honorary Doctor of Human Letters degrees from both Johnson & Wales University and from Aurora University.
Mr. Grange serves on the boards of the Gettysburg Foundation, Keranetics, the Boy Scouts Council, Therimunex, and Pharm-Olam International.
STEVE BURNS, BOARD MEMBER
Since joining Quad-C in 1994, Steve has invested in the building products, business services, specialty chemicals, packaging, transportation/logistics and food sectors. Prior to joining Quad-C, Steve worked in the Risk Arbitrage Group and Leveraged Capital Group at Paribas and the corporate development group at W.R. Grace. He holds a an M.B.A. from the Wharton School at the University of Pennsylvania and B.S. from Boston College.
Steve joined Pharm-Olam Internation’s board in 2017.
FRANK WINSLOW, BOARD MEMBER
Frank Winslow joined Quad-C in 1998 and leads investment activity in the healthcare, packaging and food sectors. Prior to joining Quad-C, Frank was a Consultant in the Quantitative Strategies Group at Public Financial Management where he advised on the issuance of municipal bonds and the use of various derivative strategies. He holds a B.A. from Princeton University.
Frank joined Pharm-Olam International's board in 2017.
ROBERT REISTETTER, BOARD MEMBER
Rob joined Quad-C in 2007. Rob’s responsibilities range from deal origination and structuring to due diligence, execution and monitoring. Prior to joining Quad-C, he worked at JLL Partners and J.P. Morgan Chase in the Leveraged Finance Group. He holds a M.B.A. from Harvard Business School and a B.S. from Ithaca College.
Rob joined Pharm-Olam International's board in 2017.